ESC 2026: True impact of poor medicine adherence laid bare in hypertensive patients
Patients who do not take blood pressure-lowering medication as prescribed are deriving little-to-no therapeutic benefit in cardiovascular disease, research shows.…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Metsera backers establish new biotech armed with China-licensed immunology asset
Fresh off a blockbuster sale to Pfizer, the investors behind Metsera are putting their expertise and business strategy to work…
-
J&J’s Imaavy secures expanded US approval in rare blood disorder
The US Food and Drug Administration (FDA) has expanded the label indication of Johnson & Johnson’s (J&J) Imaavy (nipocalimab-aahu) to…
-
Roche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate
Roche has conducted its joint-largest deal of the year so far, licensing a clinical-stage UCN2 (urocortin-2) analog being developed for…
-
Eli Lilly’s weekly insulin jab Onswik set for NHS use if approved
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Eli Lilly’s Onswik (efsitora…
-
Regeneron’s Pasatru wins FDA approval in ultra-rare ‘stone man disease’
Regeneron has won US Food and Drug Administration (FDA) approval for Pasatru (garetosmab-grts) in a rare connective tissue disorder, placing…
-
BioMarin spends up to $490m for Alesta’s bone disease candidate
BioMarin Pharmaceutical has outlaid $490m to acquire rare disease drug developer Alesta Therapeutics, though it plans to keep only one…
-
LEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain
LEO Pharma has agreed to buy the worldwide rights to Tanabe Pharma’s drug in development for photosensitive genetic disorder treatment,…
-
Moving at the speed of pharma digitalisation: driving ROI from AI and digital tools
The budgets for pharma digitalisation continue to expand at a pace where operational reality is struggling to keep up. In…
-
Sandoz targets industry patent void with $322m Henlius deal
Sandoz has entered a collaboration agreement with Shanghai Henlius Biotech that will see the two companies work together on a…